一品红：关于全资子公司馥感啉颗粒获得药物临床试验通知书的公告

Core Viewpoint - Yipinhong announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of Fuganlin granules for treating adult Qi deficiency cold [2] Group 1 - The clinical trial approval notification number is 2025LP02464 [2] - The application acceptance number for the drug is CXZL2500048 [2] - The clinical trial is specifically aimed at adults suffering from Qi deficiency cold [2]